New treatment for T-cell skin lymphoma approved in Scotland
Brentuximab vedotin (Adcetris®) is now available on the NHS in Scotland for adults with some advanced T-cell skin lymphomas.
News
New treatments and drug approvals
Read the latest news and views from Lymphoma Action.
Use the drop down filter to find the most relevant news for you.
US trial of 'off-the-shelf' CAR-T cell therapy
US company gets the go-ahead to start a trial of 'off-the-shelf' CAR-T cell therapy for people with lymphoma.
EMA recommends new lymphoma treatment options
The European Medicines Agency has recommended new treatment options for people with relapsed or refractory follicular lymphoma or diffuse large B-cell lymphoma.
Another CAR T-cell therapy approved in Scotland
Axicabtagene ciloleucel (Yescarta®) is now available on the NHS in Scotland.
Idelalisib not recommended for refractory follicular lymphoma
NICE not recommending idelalisib for use on the NHS for people with refractory follicular lymphoma.
CAR T-cell therapy approved in Scotland
Good news that tisagenlecleucel (Kymriah®) is now available on the NHS in Scotland
Improving access to CAR-T cell therapy
Lymphoma Action is continually pushing for improvements in the access to, and delivery of, CAR-T cell therapy to allow everybody who is suitable for treatment to access it.
Behind the headline: Has CAR T-cell therapy got 'cancer on the run'?
It is true that CAR T-cells are a new type of treatment that could transform the prognosis for some people with difficult-to-treat lymphoma. However, it can have serious side effects and research is still ongoing to find out the long-term effects of the treatment.
Brentuximab vedotin recommended by NICE for advanced T-cell skin lymphomas
NICE approves brentuximab vedotin for advanced primary cutaneous anaplastic large cell lymphoma, mycosis fungoides and Sézary syndrome.
New 'good practice' paper on primary mediastinal B-cell lymphoma
The British Society of Haematology has released new guidelines on the diagnosis and treatment of PMBCL.